U.S. Markets open in 42 mins

Sarepta CEO charts path forward on Duchenne drug amid stock slide

Allison DeAngelis
American City Business Journals
Sarepta CEO charts path forward on Duchenne drug amid stock slide

Sarepta has seen its share price decline in the wake of data from a small study of its gene therapy drug for Duchenne muscular dystrophy. But the Cambridge biotech is moving forward with its clinical trial work and expansion plans.